You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 5, 2024

RYANODEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Ryanodex, and when can generic versions of Ryanodex launch?

Ryanodex is a drug marketed by Eagle Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has eight patent family members in five countries.

The generic ingredient in RYANODEX is dantrolene sodium. There are five drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the dantrolene sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Ryanodex

A generic version of RYANODEX was approved as dantrolene sodium by IMPAX LABS on March 1st, 2005.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RYANODEX?
  • What are the global sales for RYANODEX?
  • What is Average Wholesale Price for RYANODEX?
Drug patent expirations by year for RYANODEX
Drug Prices for RYANODEX

See drug prices for RYANODEX

Recent Clinical Trials for RYANODEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Eagle Pharmaceuticals, Inc.Phase 3
Quintiles, Inc.Phase 2
Eagle Pharmaceuticals, Inc.Phase 2

See all RYANODEX clinical trials

US Patents and Regulatory Information for RYANODEX

RYANODEX is protected by one US patents.

Patents protecting RYANODEX

Treatment using dantrolene
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RYANODEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 ⤷  Sign Up ⤷  Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 ⤷  Sign Up ⤷  Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 ⤷  Sign Up ⤷  Sign Up
Eagle Pharms RYANODEX dantrolene sodium FOR SUSPENSION;INTRAVENOUS 205579-001 Jul 22, 2014 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RYANODEX

See the table below for patents covering RYANODEX around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2005013919 ⤷  Sign Up
European Patent Office 1435781 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 03000057 ⤷  Sign Up
Canada 2516667 TRAITEMENT AU MOYEN DE DANTROLENE (TREATMENT USING DANTROLENE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.